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In order to examine the distribution of M235T (the substitution of threonine for
methionine at position 235 codon) polymorphism genotypes of the angiotensinogen
(AGT) gene and the relationship between M235T polymorphism of the AGT gene and
hypertension, a descriptive study and a case-control study were performed among
Japanese workers.  The subjects were 2042 workers at an occupational site in Shimane
Prefecture in Japan.  The database was set up for the workers’ regular health exami-
nation in 1998.  The M235T polymorphism of the AGT gene for each worker was defined
by the mutant allele specific amplification (MASA) method.  The rates of M235M (MM),
M235T (MT) and T235T (TT) genotypes were 3.9%, 30.7% and 65.5%, respectively.
The odds ratios of MT and TT against MM for hypertension by univariate analysis
were 0.77 (95% confidence interval (CI) 0.27–2.18) and 0.77 (95% CI 0.28–2.14), respec-
tively.  The odds ratios of MT and TT against MM for hypertension, adjusted for body
mass index, fasting blood sugar, drinking habits, cigarette smoking and exercise in a
logistic regression model, were 0.90 (95% CI 0.29–2.74) and 0.87 (95% CI 0.30–2.58),
respectively.  The data from this study suggests that there may be no relationship between
the M235T polymorphism of the AGT gene and hypertension.  Further prospective
studies are needed to resolve this issue.
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The angiotensinogen (AGT) gene variant,
M235T (mutation to the threonine of the methi-
onine in amino acid codon 235), was first re-
ported in the pathogenesis of essential hyper-
tension by Jeunemaitre et al. (1992).  Essential
hypertension is a multiple factorial disease that
is complicated by the interaction of a genetic
factor and an environmental factor (Soubrier et
al., 1995).  There have been many studies inves-
tigating the hypothesis that this polymorphism,
M235T, is one of the genetic factors of essential
hypertension (Hata et al., 1994; Tiila-Riikka et
al., 1996; Borecki et al., 1997; Fu-Tien et al.,
1997; Frossard et al., 1998); however, despite
numerous studies the hypothesis remains con-
troversial.
Most of the reports regarding the relationship
between M235T and hypertension implemented a
case-control study using hospital-based data
that included a relatively small sample size.
Thus, we carried out a descriptive study and a
case-control study using  population-based data
with a large sample size in order to clarify the
involvement of M235T in hypertension.
Abbreviations:  AGT, angiotensinogen; CI, confidence interval; DBP, diastolic blood pressure; MASA, mu-
tant allele specific amplification; MM, genotype M235M; MT, genotype M235T; M235T, mutation to the
threonine of the methionine in amino acid codon 235; OD, odds ratio; PCR, polymerase chain reaction; SBP,
systolic blood pressure; TT, genotype T235T
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Subjects and Methods
Subjects
The research was approved by the ethics com-
mittee of Tottori University Faculty of Medi-
cine, and informed consent was obtained from
2042 workers in Shimane Prefecture in Japan
who received their regular medical examination
in 1998.  The case-control study comprised a
total of 402 individuals selected from the 2042
workers.  The case and control individuals were
matched by sex and age (difference within 2
years old).  The following selection criteria for
hypertensives, borderline and normotensive
subjects were applied:  (i) hypertensives, bor-
derline and normotensive blood pressure as de-
fined by systolic blood pressure (SBP) ≥ 160
mmHg and/or diastolic blood pressure (DBP) ≥
95 mmHg, 140 mmHg ≤ SBP < 160 mmHg and/
or 90 mmHg ≤ DBP < 95 mmHg, and SBP <
140 mmHg and DBP < 90 mmHg, respectively;
(ii) absence of secondary hypertension; and (iii)
absence of renal disease or renal insufficiency.
Various measurements and survey of
smoking history
Body mass index (BMI) was calculated by the
following formula:  (weight kg)/(height m)2.
The blood pressure was measured in the right
upper arm with a standard sphygmomanometer
in a sitting position.  The 1st and 5th sound of
the Korotkoff sound were used as SBP and DBP,
respectively.  Measurement of the fasting blood
sugar value was carried out using an enzymatic
method (Hexokinase, G-6-PDH, Wako, Tokyo,
Japan).  Drinking habits, cigarette smoking and
exercise were assessed using a questionnaire.
Identification of polymorphism
Genome DNA was prepared from white blood
cells with the use of a fully automatic nucleic
acid extractor (MFX-2000, Toyobo Co., Ltd.,
Osaka, Japan).  The mutant allele specific am-
plification (MASA) method was used for the
analysis of the polymorphism (Takeda et al.,
1993).  Four primers were designed.  The nor-
mal sense primer and antisense primer were 5'-
AAGACTGGCTGCTCCCTGAT-3' and 5'-
GCTGTCCACACTGGCTCCCG-3', respec-
tively.  The wild type primer and polymorphism
primer including the mutation part were 5'-
AAGACTGGCTGCTCCCTGAT-3' and 5'-
AAGACTGGCTGCTCCCTGAC-3', respec-
tively.  Polymerase chain reaction (PCR) was
performed in a TaKaRa PCR Thermal Cycler
(Takara Co., Tokyo) with a 10 µL reaction
volume containing 10 mmol/L Tris-HCl (pH
8.3), 50 mmol/L KCl, 25 µmol/L of each dNTP,
1.25 µmol/L sense primer, 1 µmol/L antisense
primer, 2 µmol/L wild type primer, 2 µmol/L
polymorphism primer, 0.1 U Ampli-Taq DNA
polymerase (Perkin Elmer, Foster City, CA) and
1.5 mmol/L MgCl2.  The initial denaturation for
3 min at 95˚C was followed by 35 cycles of
denaturation for 30 s at 95˚C, anneal-
ing for 30 s at 65˚C, and extension for
60 s at 72˚C.  PCR products were
electrophoresed in 6% polyacrylami-
de gels on a Model Cassette Electro-
phoresis Unit “DPC” (Daiichi Pure
Chemical Co., Ltd., Tokyo) and DNA
was visualized by ethidium bromide
staining.
Table 1.  Subjects related by angiotensinogen
codon 235 genotypes by age
Age   Genotype        Total
    MM       MT     TT
10–19     1(100.0)       1 (100.0)
20–29 13 (  3.6) 124 ( 34.3)   224 (62.0)   361 (100.0)
30–39 18 (  4.0) 134 ( 29.1)   304 (67.0)   454 (100.0)
40–49 21 (  3.4) 197 ( 32.3)   391 (64.2)   609 (100.0)
50–59 21 (  4.1) 143 ( 28.1)   345 (67.8)   509 (100.0)
60–69   4 (  4.5)   22 ( 24.7)     63 (70.8)     89 (100.0)
70–79   2 (10.5)     7 ( 36.8)     10 (52.6)     19 (100.0)
Total 79 (  3.9) 626 ( 30.7) 1337 (65.5) 2042 (100.0)
The percentage of individual genotypes by age is given in
parentheses.
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Table 3.  Distribution and mean value of various indices by case and control
Control Case Total P value
Normotensive Hypertensive
Genotype MM     7 (    4)     9 (    5)   16 (    4)
MT   66 (  33)   65 (  32) 131 (  33)
TT 128 (  64) 127 (  63) 255 (  63)
Total 201 (100) 201 (100) 402 (100) 0.877
BMI Mean ± SD   23.2 ±   2.9   24.8 ±   3.3   24.0 ±   3.2 0.000
Blood Sugar Mean ± SD (mg/dL) 102.6 ± 25.8 108.2 ± 22.6 105.4 ± 24.4 0.021
Drinking Never, sometimes 129 (  64) 109 (  54) 238 (  59)
Everyday   72 (  36)   92 (  46) 164 (  41)
Total 201 (100) 201 (100) 402 (100) 0.043
Smoking Never smoked or ex-smoker 141 (  70) 129 (  64) 270 (  67)
Active smoker   60 (  30)   72 (  37) 132 (  33)
Total 201 (100) 201 (100) 402 (100) 0.19
Exercise Many times   18 (    9)   14 (    7)   32 (    8)
Sometimes, never 183 (  91) 187 (  93) 370 (  92)
Total 201 (100) 201 (100) 402 (100) 0.447
The percentages are given in parentheses.
BMI, body mass index; MM, M235M; MT, M235T; TT, T235T.
Statistical analysis
SPSS software (version 8.0, SPSS Japan Inc.,
Tokyo) was used for all statistical comparisons.
The χ2 statistic was calculated to test the distri-
bution trend of each index by genotype.  Rela-
tive risks were calculated by the logistic regres-
sion analysis method.
Results
The proportions of the genotype found in this
study for M235M (MM), M235T (MT) and
T235T (TT) were 3.9%, 30.7% and 65.5%, re-
spectively (Table 1).  There was no statistically
significant relationship between distribution of
genotype and age.  The allele frequency of 235T
was 0.808.  As shown in Table 2, there was no
significant difference between the normoten-
sive, borderline and hypertensive subjects in
terms of the proportions of the genotypes.  Table
3 shows the distribution of genotype, drinking
habits, cigarette smoking and exercise, and the
mean values of BMI and fasting blood sugar re-
lated to case and control.  The mean values of
BMI and fasting blood sugar, and distribution
of drinking habits in both case and control
groups were statistically different from each
other.  In regard to the odds ratio (OD) for hy-
pertension, the ODs of MT and TT against MM
by univariate analysis were 0.77 [95% confi-
dence interval (CI) 0.27–2.18] and 0.77 (95%
CI 0.28–2.14) (Table 4).  These ODs showed
statistically higher trends in BMI, fasting blood
Table 2.  Subjects related by angiotensinogen codon 235 genotypes by blood pressure
SBP DBP Genotype Total
(mmHg) (mmHg) MM MT TT
Normotensive < 140 < 90 63 (  79.7) 500 (  79.9) 1046 (  78.2) 1609 (  78.8)
Borderline ≥ 140, < 160 ≥ 90, < 95   7 (    8.9)   61 (    9.7)   164 (  12.3)   232 (  11.4)
Hypertensive ≥ 160 ≥ 95   9 (  11.4)   65 (  10.4)   127 (    9.5)   201 (  9.8)
Total 79 (100.0) 626 (100.0) 1337 (100.0) 2042 (100.0)
The percentage of individual normotensive, borderline and hypertensive is given in parentheses.
DBP, diastolic blood pressure; MM, M235M; MT, M235T; TT, T235T; SBP, systolic blood pressure.
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sugar and drinking habits.  When the multiple
risk factors of BMI, fasting blood sugar, drink-
ing habits, cigarette smoking and exercise were
adjusted, the ODs of MT and TT against MM
were 0.90 (95% CI 0.29–2.74) and 0.87 (95%
CI 0.30–2.58), respectively, but these were not
significant.
Discussion
In the population examined in this study, the
frequency of the wild type MM was the lowest,
while that of the mutant type TT was the high-
est.  There were no significant differences in the
proportions of the genotypes among normo-
tensive, borderline and hypertensive subjects.
The odds ratios of MT and TT against MM for
hypertension analyzed by correction using vari-
ous factors were not significant, and there were
no correlations (0.90 and 0.87, respectively).
The allele frequency in the population was
higher than that of Caucasians (Jeunemaitre et
al., 1992).  This agreed with the results reported
in several studies on investigation of the allele
frequency in Japanese subjects (Iwai et al.,
1994; Kamitani et al., 1994; Morise et al., 1995;
Nishiuma et al., 1995; Sato et al., 1997).  The
allele frequency was 0.808 in the present study,
and ranged from 0.604 to 0.860 in published
studies.  This is probably because there are re-
gional differences in the genetic background of
the native Japanese.
The relationship between this genetic poly-
morphism and hypertension has been suggested
in studies performed in Japan and in other coun-
tries (Jeunemaitre et al., 1992; Hata et al., 1994;
Soubrier et al., 1995; Tiila-Riikka et al., 1996;
Borecki et al., 1997; Fu-Tien et al., 1997; Frossard
et al., 1998).  Kato et al. (1999) were the first to
cast doubt on this relationship.  The different re-
sults for the relationship between genotypes and
hypertension may be caused by the possibility
of bias in choosing controls, differences be-
tween races, regional differences in genetic back-
ground, differences in the age of subjects and
multifactors of the examined disease, because
most of the studies were hospital-based case-
control studies in a small sample size (Singer et
al., 1996).
To improve on the drawbacks of hospital-
based case-control studies in a small sample
size, we performed a population-based case-
control study and obtained no correlations
between genotypes and hypertension.  This
study was an improvement being performed in
a population-based pattern, because a case-
control study has many kinds of biases.  It is
very difficult to choose a suitable control group
and it was considered necessary to evaluate the
relationship by a cohort study which has few
information biases compared to a case-control
study.
In conclusion, there was no correlation be-
tween the M235T polymorphism of the AGT
gene and hypertension in a population-based
case-control study corrected for various factors
in Japanese subjects.  We consider it necessary
to investigate further by using the method of a
cohort study.
Table 4.  Hypertension risks estimates associated with angiotensinogen M235T gene
polymorphism and risk factors based on a case-control study
                         Univariate                      Multivariate
Odds ratio 95% CI Odds ratio 95% CI
Genotype (1) (MT versus MM) 0.766 0.269–2.179 0.895 0.293–2.735
Genotype (2) (TT versus MM) 0.772 0.279–2.135 0.873 0.295–2.583
BMI 1.191* 1.112–1.274 1.186* 1.107–1.271
Blood sugar 1.011* 1.001–1.021 1.006 0.997–1.015
Drinking 1.512* 1.012–2.260 1.450 0.941–2.234
Smoking 1.322 0.870–2.008 1.242 0.792–1.947
Exercise 1.337 0.631–2.831 1.289 0.589–2.825
* P < 0.05.
BMI, body mass index; CI, confidence interval; MM, M235M; MT, M235T; TT, T235T.
Angiotensinogen gene and hypertension
83
Acknowledgments:  This research was supported in
part by a Grant-in-Aid (11470096) from the Ministry
of Education, Japan.
References
 1 Borecki IB, Province MA, Ludwig EH, Ellison
RC, Folsom AR, Heiss G, et al.  Associations of
candidate loci angiotensinogen and angiotensin-
converting enzyme with severe hypertension:  the
NHLBI family heart study.  Am Epidemiol 1997;
7:13–21.
 2 Frossard PM, Hill SH, Elshahat YI, Obineche
EN, Bokhari AM, Lestringant GG, et al.  Associ-
ations of angiotensinogen gene mutations with
hypertension and myocardial infarction in a gulf
population.  Clin Genet 1998;54:285–293.
 3 Fu-Tien C, Kwan-Lih H, Chuen-Den T, Wei-Hon
H, Huey-Ming L, Tser-Haw C, et al.  Molecular
variant M235T of the angiotensinogen gene is asso-
ciated with essential hypertension in Taiwanese.  J
Hypertension 1997;15:607–611.
 4 Hata A, Namikawa C, Sasaki M, Sato K,
Nakamura T, Tamura K, et al.  Angiotensiogen as
a risk factor for essential hypertension in Japan.  J
Clin Invest 1994;93:285–1287.
 5 Iwai N, Ohmichi N, Nakamura Y, Mitsunami K,
Kinoshita M.  Molecular variants of the angio-
tensinogen gene and hypertension in a Japanese
population.  Hypertens Res 1994;17:117–121.
 6 Jeunemaitre X, Soubrier F, Kotelevsev YV,
Lifton RP, Williams CS, Charru A, et al.  Molec-
ular basis of human hypertension:  role of angio-
tensinogen.  Cell 1992;71:169–180.
 7 Kamitani A, Rakugi H, Higaki J, Yi Z, Mikami
H, Miki T, et al.  Association analysis of a poly-
morphism of the angiotensinogen with essential
hypertension in Japanese.  J Hum Hypertens
1994;8:521–524.
 8 Kato N, Sugiyama T, Morita H, Kurihara H,
Yamori Y, Yazaki Y.  Angiotensinogen gene and
essential hypertension in the Japanese:  extensive
association study and meta-analysis on six report-
ed studies.  J Hypertension 1999;17:757–763.
 9 Morise T, Takeuchi Y, Takeda R.  Rapid detec-
tion and prevalence of the variants of the angio-
tensinogen gene in patients with essential hyper-
tension.  J Intern Med 1995;237:175–180.
10 Nishiuma S, Kario K, Kayaba K, Nagio N,
Shimada K, Matsuo T, et al.  Effect of the angio-
tensinogen gene Met235 → Thr variant on blood
pressure and other cardiovascular risk factors in
two Japanese populations.  J Hypertension 1995;
13:717–722.
11 Sato N, Katsuya T, Rakugi H, Takami S, Nakata
Y, Miki T, et al.  Association of variants in criti-
cal core promoter element of angiotensinogen
gene with increased risk of essential hypertension
in Japanese. Hypertension 1997;30:321–325.
12 Singer DRJ, Missouris CG, Jeffery S.  Angio-
tensin converting enzyme gene polymorphism:
what to do about all the confusion?  Circulation
1996;94:236–239.
13 Soubrier F, Lathrop GM.  The genetic basis of
hypertension.  Curr Opin Nephrol Hypertens
1995;4:177–181.
14 Takeda S, Ichii S, Nakamura Y.  Detection of K-
ras mutation in sputum by mutant-allele-specific
amplification (MASA).  Hum Mutation 1993;2:
112–117.
15 Tiila-Riikka K, Heikki K, Asko OR, Mauno L,
Antti R, Y Antero K, et al.  Variation at the angio-
tensin-converting enzyme gene and angiotensi-
nogen gene loci in relation to blood pressure.
Hypertension 1996;28:1070–1075.
Received December 20, 2000; accepted January 10, 2001
Corresponding author:  Prof. Takuji Kishimoto
